- Visibility 35 Views
- Downloads 21 Downloads
- Permissions
- DOI 10.18231/j.ijirm.12686.1943244482
-
CrossMark
Screening for latent TB: A review of interferon-gamma release assays and the tuberculin skin test (TST)
- Author Details:
-
Saurabh Chhotalal Norris
-
Binda Prakashbhai Pipaliya
-
Himani Bhardwaj Pandya
-
Rachana Dhirubhai Patel *
-
Tanuja Bakul Javadekar
Saurabh Chhotalal Norris
Binda Prakashbhai Pipaliya
Himani Bhardwaj Pandya
Rachana Dhirubhai Patel *
Latent tuberculosis infection (LTBI) affects a substantial portion of the global population and represents a key reservoir for future active tuberculosis (TB) cases. Early and accurate detection of LTBI is essential for TB control and elimination strategies, particularly in high-burden countries like India. The Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs), including QuantiFERON-TB Gold and T-SPOT.TB, are the principal diagnostic tools for LTBI. TST is simple, low-cost, and suitable for peripheral healthcare settings, but its specificity is limited by prior BCG vaccination and environmental non-tuberculous mycobacteria. IGRAs provide improved specificity by detecting T-cell responses to Mycobacterium tuberculosis-specific antigens, offer single-visit testing, and are particularly useful in immunocompromised or BCG-vaccinated populations. This review evaluates the diagnostic principles, comparative performance, predictive value for progression to active TB, operational challenges, cost-effectiveness, and guideline-based recommendations for TST and IGRA. Emphasis is placed on India-specific implementation strategies, including tiered diagnostic approaches, quality assurance, and use in special populations, highlighting the potential of these tools to optimize LTBI screening and accelerate progress toward national TB elimination goals.
References
- Houben R, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016;13(10)e1002152.
- Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76.
- Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177–84.
- Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest. 2010;137(4):952–68.
- World Health Organization. WHO operational handbook on tuberculosis. Module 3: Diagnosis – rapid diagnostics for tuberculosis detection. Geneva: WHO; 2024. Available from: https://www.who.int/publications/i/item/9789240089501
- Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):45–55.
- Abubakar I, Drobniewski F, Southern J, Sitch AJ, Jackson C, Lipman M, et al. Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): A prospective cohort study. Lancet Infect Dis. 2018;18(10):1077–87.
- Salgado E, Gómez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev Clin Immunol. 2011;7(3):329–40.
- Prakash Babu S, Ezhumalai K, Raghupathy K, Sundaresan M, Jain K, Narasimhan PB, et al. Comparison of IGRA and TST in the diagnosis of latent tuberculosis among women of reproductive age in South India. Indian J Tuberc. 2023;70(1):12–6.
- Abdul-Ghani R, Al-Awadi A, Al-Aghbari N, Al-Mikhlafy AA, Abdulmoghni SS, Al-Dobai SS, et al. Latent tuberculosis infection and diagnostic performance of the tuberculin skin test among type 2 diabetics in Sana'a city, Yemen. BMC Infect Dis. 2024;24(1):1005.
- Sousa S, Rocha D, Silva JC, Ribeiro AI, Gonçalves G, Almeida Á, et al. Comparing the cost-effectiveness of two screening strategies for latent tuberculosis infection in Portugal. Pulmonology. 2021;27(6):493–9.
- Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole- blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med. 2011;183(1):88–95.
- Ma Y, Xu Y, Cao X, Chen X, Zhong Y. Diagnostic value of interferon-γ release assay in HIV-infected individuals complicated with active tuberculosis: a systematic review and meta-analysis. Epidemiol Infect. 2021;149:e204.
- Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017;64(2):111–5.
- Mandalakas AM, Kirchner HL, Walzl G, Gie RP, Schaaf HS, Cotton MF, et al. Optimizing the detection of recent tuberculosis infection in children in a high tuberculosis-HIV burden setting. Am J Respir Crit Care Med. 2015;191(7):820–30.
- Naqvi S, Cantu Y, Ong Uti S, Cavazos D, Johnson A, Salazar CI, et al. Successes and challenges of latent TB screening and treatment in a high-prevalence US region. Int J Tuberc Lung Dis. 2022;26(8):720–6.
- World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: WHO; 2018. Report No.: WHO/CDS/TB/2018.4. ISBN:
- Central TB Division. Guidelines for Programmatic Management of Tuberculosis Preventive Treatment in India. New Delhi: Ministry of Health and Family Welfare, Government of India; 2021.
- Ministry of Health and Family Welfare. INDEX-TB Guidelines: Management of extrapulmonary tuberculosis in India. Revised ed. New Delhi: MoHFW; 2022.
- Mishra G, Mulani J. Latent Multi-drug Resistant Tuberculosis: An Unaddressed Problem. Arch Pulmonol Respir Care. 2020;6(1):84–
- van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One. 2009;4(12):e8517.
- Ringshausen FC, Nienhaus A, Torres Costa J, Knoop H, Schlösser S, Schultze-Werninghaus G, et al. Within-subject variability of Mycobacterium tuberculosis-specific gamma interferon responses Norris et al / IP Indian Journal of Immunology and Respiratory Medicine 2025;10(3):104-109 109 in German health care workers. Clin Vaccine Immunol. 2011;18(7):1176–82.
- Knierer J, Gallegos Morales EN, Schablon A, Nienhaus A, Kersten JF. QFT-Plus: a plus in variability? - Evaluation of new generation IGRA in serial testing of students with a migration background in Germany. J Occup Med Toxicol. 2017;12:1.
- Gaur RL, Pai M, Banaei N. Impact of blood volume, tube shaking, and incubation time on reproducibility of QuantiFERON-TB gold in-tube assay. J Clin Microbiol. 2013;51(11):3521–6.
- Rebecca BP, Angamuthu D, Watson B, Beena ET, Balaguru S, Premkumar J, et al. Can Students Learn from Their Co-Students About Tuberculosis? Outcomes from Student-Friendly Quasi- Experimental Intervention Study in India. Indian J Community Med. 2022;47(4):527–30.
- Shah H, Patel J, Rai S, Sen A. Advancing tuberculosis elimination in India: A qualitative review of current strategies and areas for improvement in tuberculosis preventive treatment. IJID Reg. 2024;14:100556.
- Thakur G, Thakur S, Thakur H. Status and challenges for tuberculosis control in India - Stakeholders' perspective. Indian J Tuberc. 2021;68(3):334–9.
- Alvi Y, Philip S, Anand T, Chinnakali P, Islam F, Singla N, et al. Situation Analysis of Early Implementation of Programmatic Management of Tuberculosis Preventive Treatment among Household Contacts of Pulmonary TB Patients in Delhi, India. Trop Med Infect Dis. 2024;9(1):24.
- World Health Organization. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: Policy statement. Geneva: WHO; 2011. Available from: https://www.who.int/publications/i/item/9789241502672.
- Sachdeva KS, Kumar A, Dewan P, Kumar A, Satyanarayana S. New vision for Revised National Tuberculosis Control Programme (RNTCP): Universal access—“Reaching the un-reached. Indian J Med Res. 2012;135(5):690–4.
- Nath R, Goswami Mahanta T, Nirmolia N, Choudhury G, Chetri M, Gogoi G, Baruah R. Prevalence of tuberculosis infection in immunological-competent prison inmates using Interferon Gamma Release Assay (IGRA) in a central jail of Assam, India. Clin Epidemiol Global Health. 2025;34:102086.
- Palanivel J, Sounderrajan V, Thangam T, Rao SS, Harshavardhan S, Parthasarathy K. Latent Tuberculosis: Challenges in Diagnosis and Treatment, Perspectives, and the Crucial Role of Biomarkers. Curr Microbiol. 2023;80(12):392.
- Stop TB Partnership. Global Drug Facility: Product catalogue 2025. Geneva: Stop TB Partnership; 2025. Available from: https://www.stoptb.org/sites/default/files/documents/2024.12.16_g df_medicines_catalog_Jan_2025.pdf
- Souza FM, Steffen RE, Pinto MFT, Prado TND, Maciel ELN, Trajman A. TB antigen-based skin tests and QFT-Plus for Mycobacterium tuberculosis infection diagnosis in Brazilian healthcare workers: a cost-effectiveness analysis. Cad Saude Publica. 2025;41(1):e00178623.
- Campbell JR, Johnston JC, Cook VJ, Sadatsafavi M, Elwood RK, Marra F. Cost-effectiveness of Latent Tuberculosis Infection Screening before Immigration to Low-Incidence Countries. Emerg Infect Dis. 2019;25(4):661–71.
- Goscé L, Allel K, Hamada Y, Korobitsyn A, Ismail N, Bashir S, et al. Economic evaluation of novel Mycobacterium tuberculosis specific antigen-based skin tests for detection of TB infection: A modelling study. PLOS Glob Public Health. 2023;3(12):e0002573.
- Meier NR, Volken T, Geiger M, Heininger U, Tebruegge M, Ritz N. Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children-A Systematic Review and Meta-Analysis. Front Pediatr. 2019;7:208.
- Oni T, Gideon HP, Bangani N, Tsekela R, Seldon R, Wood K, et al. Risk factors associated with indeterminate gamma interferon responses in the assessment of latent tuberculosis infection in a high- incidence environment. Clin Vaccine Immunol. 2012;19(8):1243–7.
- Šegović M, Mihatov Štefanović I, Pavić I. The role of interferon- gamma release assays in diagnosis of latent tuberculosis infection in children. Acta Clin Croat. 2023;62(3):527–38.
- Sun L, Tian JL, Yin QQ, Xiao J, Li J, Guo Y, et al. Performance of the Interferon Gamma Release Assays in Tuberculosis Disease in Children Five Years Old or Less. PLoS One. 2015;10(12):e0143820.
- Meier NR, Volken T, Geiger M, Heininger U, Tebruegge M, Ritz N. Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children-A Systematic Review and Meta-Analysis. Front Pediatr. 2019;7:208.